LYEL - Lyell Immunopharma gets FDA nod to start phase 1 trial of its cancer therapy LYL845
- Lyell Immunopharma ( NASDAQ: LYEL ) on Thursday said the U.S. FDA had cleared its investigational new drug application to start a phase 1 trial for its experimental cancer therapy LYL845.
- LYEL stock +4.1% to $8.42 after hours.
- LYL485 is a tumor infiltrating lymphocyte enhanced with LYEL's reprogramming technology.
- The early-stage trial will evaluate LYL485 as a treatment for melanoma, the most serious type of skin cancer, LYEL said in a statement .
- The trial will also have expansion cohorts for patients with non-small cell lung cancer and colorectal cancer.
- Initial data presentation from the trial is expected in 2024.
For further details see:
Lyell Immunopharma gets FDA nod to start phase 1 trial of its cancer therapy LYL845